On March 30, 2026, I attended RISE Together: Data Sharing Across the Rare Disease Ecosystem [1] expecting a discussion about the platforms and infrastructure needed to move data more efficiently across systems. Instead, what surfaced over the course of the day was something more fundamental, and more difficult to resolve. The rare disease field is …
Continue reading “When the Data Exists but Doesn’t Travel: Lessons from RISE Together 2026”
On March 25, 2026, I attended MAX: Medical Affairs eXcellence Forum, Canada’s first forum dedicated entirely to medical affairs in biopharma. Organized by Agilis Health and held at the Sheraton Toronto Airport, it brought together 140+ professionals spanning Medical Affairs, Pharma, Clinical Research, Regulatory, and Medical Communications for a full day of candid, high-calibre conversation. …
Traditional drug development is one of the most expensive and failure-prone endeavors in science. Bringing a new drug to market typically takes over a decade, with cost estimates exceeding two billion dollars and failure rates upwards of 90% [1]. Less than 10% of target drugs even make it to Phase I Trials. AI is now …
Continue reading “AI in Healthcare (3): The Molecule Will Design Itself Now—AI in Drug Discovery”
The first article of this series argued that the peptide boom is not just a fringe fad but a parallel ecosystem, built by people who feel conventional medicine is too slow, too narrow, or too inaccessible for the goals they care about. In our second article, we asked how far bodily autonomy should extend when …
Continue reading “The Peptide Paradox (3): When the System Has No Middle Ground”
The gray‑market peptide boom is no longer a fringe curiosity. It has become a growing parallel ecosystem for people who feel conventional medicine is too slow, too restrictive, too expensive, and often not designed for the kinds of outcomes they care about. In this three‑part series we examine that ecosystem: how mistrust of institutions is …
Continue reading “The Peptide Paradox (1): When Institutional Distrust Drives Alternative Science”